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Background: Despite encouraging results with the proteasome inhibitor bortezomib in the treatment of
hematologic malignancies, emergence of resistance can limit its efficacy, hence calling for novel strategies to
overcome bortezomib-resistance. We previously showed that bortezomib-resistant human leukemia cell lines
expressed significantly lower levels of immunoproteasome at the expense of constitutive proteasomes, which harbored
point mutations in exon 2 of the PSMB5 gene encoding the β5 subunit. Here we investigated whether up-regulation of
immunoproteasomes by exposure to interferon-γ restores sensitivity to bortezomib in myeloma and leukemia cell lines
with acquired resistance to bortezomib.
Methods: RPMI-8226 myeloma, THP1 monocytic/macrophage and CCRF-CEM (T) parental cells and sub lines with
acquired resistance to bortezomib were exposed to Interferon-γ for 24-48 h where after the effects on proteasome
subunit expression and activity were measured, next to sensitivity measurements to proteasome inhibitors bortezomib,
carfilzomib, and the immunoproteasome selective inhibitor ONX 0914. At last, siRNA knockdown experiments of β5i
and β1i were performed to identify the contribution of these subunits to sensitivity to proteasome inhibition. Statistical
significance of the differences were determined using the Mann-Whitney U test.
Results: Interferon-γ exposure markedly increased immunoproteasome subunit mRNA to a significantly higher level in
bortezomib-resistant cells (up to 30-fold, 10-fold, and 6-fold, in β1i, β5i, and β2i, respectively) than in parental cells.
These increases were paralleled by elevated immunoproteasome protein levels and catalytic activity, as well as HLA
class-I. Moreover, interferon-γ exposure reinforced sensitization of bortezomib-resistant tumor cells to bortezomib
and carfilzomib, but most prominently to ONX 0914, as confirmed by cell growth inhibition studies, proteasome
inhibitor-induced apoptosis, activation of PARP cleavage and accumulation of polyubiquitinated proteins. This
sensitization was abrogated by siRNA silencing of β5i but not by β1i silencing, prior to pulse exposure to interferon-γ.
Conclusion: Downregulation of β5i subunit expression is a major determinant in acquisition of bortezomib-resistance
and enhancement of its proteasomal assembly after induction by interferon-γ facilitates restoration of sensitivity in
bortezomib-resistant leukemia cells towards bortezomib and next generation (immuno) proteasome inhibitors.
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Bortezomib is a tight binding yet reversible proteasome
inhibitor that is indicated for treatment of newly diag-
nosed and relapsed multiple myeloma (MM) [1], and is
currently being tested in clinical trials for childhood
leukemia [2]. In July 2012, the epoxyketone-based prote-
asome inhibitor carfilzomib [3] was approved in the US
for patients with relapsed and refractory MM who re-
ceived at least two prior therapies (including bortezomib
and an immunomodulatory agent) and progressed on or
within 60 days of completion of the last therapy [4,5].
Notwithstanding promising initial results, acquired resist-
ance to bortezomib is an emerging factor, which may limit
its efficacy in the treatment of hematologic malignancies.
The clinical impact of acquired resistance has been dem-
onstrated in poor responses of MM patients who were
re-treated with bortezomib [6]. Although bortezomib-
retreatment was effective, the response rates as well as
the duration of response were decreased as compared to
initial therapy, which may point to the development of
bortezomib-resistance in (a subgroup of) patients [7]. To
investigate possible mechanisms of bortezomib resis-
tance, we previously developed in vitro cell line models
of hematologic malignancies in which acquired resistance
to bortezomib was provoked by chronic exposure to
gradually increasing bortezomib concentrations [8,9].
These bortezomib-resistant cell lines were characterized
by an increased expression of the constitutive prote-
asome subunit β5 harboring mutations in the bortezomib-
binding pocket, along with a decreased expression of
non-mutated immunoproteasome subunits. Furthermore,
these bortezomib-resistant cells displayed cross-resistance
to other proteasome inhibitors that target β-subunits of
the proteasome [9]. The constitutive proteasome has three
proteolytically active subunits; β5 (PSMB5), β1 (PSMB6),
and β2 (PSMB7) which harbor the chymotrypsin-like,
caspase-like, and trypsin-like catalytic activities, respect-
ively. Upon exposure to inflammatory cytokines, including
interferon-γ (IFN-γ) or tumor necrosis factor α (TNF-α),
the constitutive subunits are exchanged for immuno-
proteasome subunits β5i (LMP7) β1i (LMP2), and β2i
(MECL-1) [10]. While β5i harbors chymotrypsin-like
activity as in β5, whereas β2i and β2 contain trypsin-
like activity, β1i displays chymotrypsin-like activity ra-
ther than β1-associated caspase-like activity [11,12]. The
immunoproteasome is dominantly expressed in cells of
hematologic origin and its primary function was origin-
ally attributed to improve MHC Class I antigen presen-
tation. To this end, the immunoproteasome can produce
a distinct set of peptides from the constitutive prote-
asome because the immunoproteasome cleaves prefera-
bly after hydrophobic and basic amino acids (cleaved by
chymotrypsin-like and trypsin-like activities, respectively)
that can better fit MHC Class I molecules [13]. Therefore,peptides generated by the immunoproteasome may be
more efficient in T-cell activation than peptides from the
constitutive proteasome. In addition, Seifert and colleagues
[14] provided evidence to implicate the immunoproteasome
in protein degradation after immune response-induces
stress, and that the immunoproteasome is more efficient
than the constitutive proteasome in controlling the protein
degradation process. However, this property of immuno-
proteasomes was recently challenged and warrants further
investigations [15,16]. Several studies [17-19] have reported
higher immunoproteasome expression compared to consti-
tutive subunits in B-cell malignancies, underscoring the
potential importance of the immunoproteasome in the
homeostasis of hematologic diseases [20]. However, al-
though there is evidence for pre-clinical activity of the
β5i-specific proteasome inhibitor ONX 0914 [21] in experi-
mental autoimmune disease models, data justifying its use
for the treatment of hematologic malignancies is limited [2].
Tumor cells have the capacity to modulate immuno-
proteasome function to escape immune surveillance
[22]. This condition may also arise in hematologic tumor
cells with acquired resistance to bortezomib due to the ac-
quisition of mutations in the PSMB5 gene encoding the
constitutive β5 subunit. Since its immunoproteasome β5i
counterpart does not harbor mutations, downregulation of
immunoproteasome in bortezomib-resistant hematologic
tumor cell lines may provide a mechanism to escape tar-
geting by bortezomib. From a therapeutic perspective, this
would imply that tipping the balance towards upregulation
of immunoproteasome expression could re-confer sensiti-
vity to bortezomib or next generation proteasome inhibi-
tors designed to target immunoproteasomes [20,23].
Original studies by Altun et al [24] showed that in-
flammatory cytokines such as IFN-γ and TNFα were
efficient inducers of immunoproteasomes in MM cell
lines, including 8226 cells. Functional studies by Busse
et al [25] showed that exposure to IFN-γ enhanced
bortezomib-sensitivity in B-cell lines by 50%, for which the
underlying mechanism was unexplored. Furthermore, the
β5i immunoproteasome subunit played a critical role in
IFN-γ-induced apoptosis by degradation of Mcl-1 in athero-
sclerotic lesion-derived cells [26].
In this study, we explored whether IFN-γ-induced
upregulation of immunoproteasome expression in
bortezomib-resistant leukemia cell lines in which both
immunoproteasome expression is suppressed and mu-
tated β5 subunits are overexpressed can serve as a thera-
peutic strategy to restore sensitivity towards bortezomib,
carfilzomib and ONX 0914.
Methods
Cell culture
Human T-cell ALL CCRF-CEM cells, human myeloid
leukemia THP1 cells, and human multiple myeloma
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tured in RPMI-1640 medium containing 2 mM glutamine
(Invitrogen/Gibco, Carlsbad, CA, USA) supplemented
with 10% fetal calf serum (Greiner Bio-One, Alphen
a/d Rijn, The Netherlands) and 100 μg/ml penicillin/
streptomycin (Invitrogen) at 5% CO2 and 37°C. Cell cul-
tures were seeded at a density of 3×105 cells/ml and
refreshed twice weekly. Bortezomib-resistant sublines of
these cell lines were established previously [8,9]. Authen-
ticity of bortezomib-resistant and parental cell lines was
verified by STR marker analysis for D12S1045, D8S1132,
D19S253, and D17S1293.
Antibodies, drugs and reagents
Antibodies to proteasome subunits β1, β2, β5, β1i, and
β5i were purchased from Enzo Life Sciences (Farmingdale,
NY, USA). In addition, anti-actin (clone C4) was purchased
from Millipore (Temecula, CA, USA), anti-NOXA anti-
body from Abcam (Cambridge, UK), anti-ubiquitin (P4D1)
from Santa Cruz Biotechnology (Santa Cruz, CA, USA)
and the IRDye infrared secondary labeled antibodies was
from LI-COR Biosciences (Lincoln, NE, USA). Bortezomib
was provided by Millennium Pharmaceuticals (Cambridge,
MA, USA). The epoxyketone-based proteasome inhibitors
carfilzomib and ONX 0914 were provided by Onyx
Pharmaceuticals, Inc. (South San Francisco, CA, USA).
IFN-γ was purchased from Sanquin (Amsterdam, the
Netherlands).
Proteasome active site ELISA
An ELISA-based assay (Pro-CISE) for quantitative as-
sessment of active constitutive and immunoproteasome
subunits was performed as previously described [27].
Briefly, cell lysate was incubated with a biotinylated pro-
teasome active-site binding probe. Lysate was then dena-
tured, and subunits bound to probe were isolated with
streptavidin-conjugated sepharose beads. Individual sub-
units were probed with subunit-specific primary anti-
bodies, followed by HRP-conjugated secondary antibodies.
A chemiluminescent substrate was used to generate signal
associated with HRP binding, which was read on a lumi-
nometer. Absolute values of nanograms of subunit per
microgram of total protein were based on a purified prote-
asome standard curve. Protein quantification was per-
formed utilizing the Pierce BCA Protein Assay (Thermo
Scientific, Rockford, IL, USA).
Lightcycler quantitative PCR
Lightcycler® 480 SYBR Green I Master was used to
quantify expression levels of mutated and unmutated al-
lele in the bortezomib-resistant cell lines. Primers spe-
cific for the Ala49Thr mutation, primers specific for the
unmutated allele, and primers for total PSMB5 were de-
veloped (Tib-molbiol, Germany) (Additional file 1). GUSwas used as housekeeping gene. All primers were used
at 0.5 μM each. 5 μl of cDNA template was added to the
PCR mix. Results were analysed by advanced relative
quantification using the comparative cycle time (Ct)
method by Lightcycler 480 Instrument Software version
1.5 (Roche Diagnostics, Switzerland).
Cell growth inhibition assay
In vitro drug sensitivity was determined using the 4-day
MTT cytotoxicity assay [28]. Prior to these experiments,
bortezomib-resistant cells were cultured in bortezomib-
free medium for at least 4 days. Cells were then pre-
exposed for 48 h to 100 U/ml IFN-γ and then subjected to
various concentrations of bortezomib (range: 0.001 μM –
2 μM), CFZ (0.008 nM - 15.6 nM for the parental cell
lines; 0.0005 μM - 1 μM for bortezomib-resistant lines), or
ONX 0914 (0.008 μM – 16 μM) for 4 days. For siRNA ex-
periments, cells were incubated with 100 nM siRNA for
24 h before adding 100 U/ml IFN-γ for 48 hours, followed
by the same concentration ranges of the drugs as specified
above. The IC50 value was defined as the drug concentra-
tion necessary to inhibit 50% of the cell growth compared
to growth of the untreated control cells.
Proteasome activity
Intact-cell based caspase-like, trypsin-like, and
chymotrypsin-like proteasome activities
An intact cell-based assay to measure basal and IFN-γ-
induced upregulation of caspase-like, trypsin-like, and
chymotrypsin-like proteasome activities was conducted
by using a Proteasome-Glo assay kit according to the
manufacturer’s instructions (Promega, Madison, WI).
Before determination of proteasome activity, cells were
exposed to 100 U/ml IFN-γ for 24 h, 48 h, 72 h, and 96 h
at 37°C in a white flat-bottomed 96-well plate (Greiner
Bio-one, The Netherlands) at a density of 10 000 cells per
well in a total volume of 50 μl. After 15-min incubation
period with luminogenic substrates, luminescence was
determined with an Infinite 200 Pro microplate reader
(Tecan, Giessen, The Netherlands). Background measure-
ments of cell-free medium plus substrate were subtracted
from cell measurements.
HLA Class I expression
HLA Class I expression was determined using HLA-
ABC FITC antibody (5 μg/ml) (eBioscience, San Diego,
CA, USA) and mouse IgG2a antibody (5 μg/ml) as iso-
type control. Cells were measured on the FACSDiva, and
analyzed using CELLQUEST software.
Specific β5, β5i, and β1i subunit activities in cell extracts
For measurement of specific β5, β5i, and β1i activities,
the Ac-WLA-AMC, Ac-ANW-AMC, and Ac-PAL-AMC
fluorogenic substrates were used, respectively [29]. Cells
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mM ethylenediaminetetraacetic acid (EDTA) was added
at pH 8.0 and samples were frozen at -80°C until ana-
lysis. Samples were thawed and centrifuged at 10,000 g
for 10 minutes at 4°C. The supernatant was removed
and assayed for protein content using the BioRad Protein
Assay following the manufacturer's protocol (BioRad,
Hercules, CA, USA).
Assays were performed at 37°C in a final volume of
200 μL using 96-well black opaque plates (Greiner bio-one,
Germany). Protein extracts were diluted to 200 μg/mL in
5 mM EDTA at pH 8.0. Diluted protein extract aliquots
(50 μL) were dispensed per well, giving 10 μg of protein
extract per reaction. Reactions were initiated by addition
of 150 μL of 133 μM peptide-AMC substrate in 20 mM
N-[2-Hydroxyethyl]piperazine-N-[2-ethanesulfonic acid]
(HEPES), pH 7.4, containing 0.5 mM EDTA. Peptidase
activity was measured by kinetic monitoring of 7-amino-4-
methylcoumarin (AMC) production over two hours with a
Biotek plate reader (Winooski, VT, USA) and analyzed by
GraphPad Prism software (La Jolla, CA, USA) with linear
regression analysis.
RNA interference
For RNA interference experiments all targeted and non-
targeted siRNA constructs were obtained from Dharmacon
(Lafayette, USA) and all experiments were performed in
6well plates. THP1/BTZ200 cells were cultured following
the DharmaFECT general transfection protocol conditions
for THP1 cells. Briefly, prior to transfection, cells were cul-
tured overnight at a density of 3 × 105 cells/ml in RPMI-
1640 medium supplemented with 10% FCS. Cells were
transfected using Dharmafect 2 and 100 nM of PSMB8 or
PSMB9 ON-TARGETplus SmartPool siRNA. As negative
control 100 nM ON-TARGETplus siControl non-targeting
siRNA was used and the GAPDH siRNA pool was included
as a positive control. The transfection methods had no ef-
fect on cell growth. At several time points, transfection-
efficiency was determined by mRNA expression analysis.
24 h after siRNA transfection when >80% knockdown was
established, IFN-γ (100 U/ml) was added for 24 h (or 48 h
when indicated), followed by bortezomib administration.
Protein expression/Western blotting
Protein expression of proteasome subunits was deter-
mined by Western blotting, as previously described [9].
Protein bands were quantified by Odyssey software,
corrected for background, and normalized by β-actin
to correct for loading differences within blots.
cDNA synthesis of proteasome subunits and quantitative
RT-PCR
After RNA isolation by utilizing the RNAeasy Mini kit
(Qiagen, Valencia, CA, USA), cDNA was synthesizedusing RT buffer (Invitrogen), containing 5 mM DTT
(Invitrogen), 2 mM dNTP (Roche), 96 μg/ml pdN6
(Roche), 0.75 U/μl M-MLV (Invitrogen) and 2 U/μl RNAsin
(HT Biotechnology Ltd., Cambridge, UK). mRNA expres-
sion levels of proteasome subunits PSMB5, PSMB6,
PSMB7, PSMB8, PSMB9, PSMB10, and β-glucuronidase
as a reference were quantified using real-time PCR ana-
lysis (Taqman) on an ABI Prism 7700 sequence detection
system (PE Applied Biosystems, Nieuwerkerk a/d IJssel,
The Netherlands). For PSMB5, a Taqman gene expres-
sion assay was used according to the manufacturers’
instructions (Hs00605652_m1, Applied Biosystems). All
other primers and probes were designed using Primer
Express software (Applied Biosystems) and are indicated
in Additional file 1. Probes were labeled with 5’-FAM and
3’-BHQ1 as a reporter. Real-time PCR was performed in
a total reaction volume of 25 μl containing TaqMan buf-
fer A (Applied Biosystems), 4 mM MgCl2, 0.25 mM of
each dNTP (Amersham Pharmacia Biotech) and 1.25 U
AmpliTaq Gold DNA polymerase (Applied Biosystems).
Samples were heated for 10 min at 95°C to activate the
AmpliTaq Gold DNA polymerase and amplified during
40 cycles of 15 s at 95°C and 60 s at 60°C. Relative mRNA
expression levels of the target genes in each sample were
calculated using the comparative cycle time (Ct) method.
The Ct of the target gene was normalized to the GUS Ct
value by subtracting the GUS Ct value from the target
Ct value. The mRNA expression level for each target
PCR relative to GUS was calculated using the following
equation: mRNA expression = 2(Ct target-Ct GUS) × 100%.
Statistical analysis
A logistic (or Emax) model was chosen to model the
sigmoid-shaped relationship between concentration of
the drug and percentage growth allowing for different
parameters values for the experiments without and with
IFN-γ. The expected percentage growth was assumed to
be of the following parametric form
E %Growth½  ¼ Maxþ 1INFΔMax
1þ concentrationIC50þ1INFΔIC50
 Hill50þ1INFΔHill ;
where 1INF = 0 and 1 for experiments without and with
IFN-γ, respectively. The parameters Max, IC50, and Hill
model the maximum of the percentage growth, the con-
centration at which the percentage growth is 50% of the
maximum and the slope of the curve for the experi-
ments without IFN-γ. Parameters ΔMax, ΔIC50, and
ΔHill model the change in these parameters as a result
of adding IFN-γ. Our models included additive random
effects for replicate and a residual error which were as-
sumed to be normally distributed and independent.
Nonlinear mixed models were fitted in SAS version 9.2
separately for each drug and cell line combination.
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pression and proteasome activity were determined using
the Mann-Whitney U test. Statistical significance was
achieved when P < 0.05. Statistical analyses were per-
formed using SPSS (version 20.0).
Results
Characterization of bortezomib-sensitive and
bortezomib-resistant hematologic tumor cell lines
Cell lines were of multiple myeloma (8226), T-cell
leukemia (CCRF-CEM) and myelomonocytic leukemia
(THP1) origin and their bortezomib-resistant sublines dis-
played 40-150 fold bortezomib resistance upon cell growth
inhibition [8,9]. When studying the absolute protein
expression in ng subunit/μg total protein of the catalytic-
ally active subunits in wild type (WT) and bortezomib-
resistant sublines, all WT tumor cell lines harbored a lower
amount of immunoproteasomes (β1i + β2i + β5i) than
constitutive proteasomes (β1 + β2 + β5) (8226/WT: 24%
vs. 76%, THP1/WT: 43% vs. 57%, and CEM/WT: 37%
vs. 63%, respectively). All three bortezomib-resistant
sublines displayed a decrease in immunoproteasome
expression while an increase in constitutive subunits
was observed (8226/BTZ100: 16% vs. 84%, THP1/
BTZ200: 18% vs. 82%, and CEM/BTZ200: 16% vs.
84%, respectively) (Figure 1). Additionally, total pro-
teasome content per μg total protein was increased in
CEM/BTZ200 and THP1/BTZ200 cells compared to
their WT counterparts (19.8 ng/μg vs. 27.3 ng/μg for
CEM/BTZ200 and 16.5 ng/μg vs. 31.7 ng/μg for THP1/
BTZ200 cells), whereas the proteasome content in 8226/Figure 1 Proteasome subunit expression in bortezomib-resistant and
cells. Protein expression levels of constitutive proteasome subunits (β5, β1
determined by ProCISE and expressed in ng/μg total protein for 8226/WT,
Percentages of individual subunits are given. Results depicted represent thBTZ100 was similar to that of 8226/WT (21.2 ng/μg vs.
23.7 ng/μg) (Figure 1).
IFN-y exposure tips balances from constitutive
proteasomes to immunoproteasomes
Since low levels of immunoproteasome expression ap-
peared to be a characteristic feature of bortezomib-resistant
tumor cell lines, we aimed at increasing immunopro-
teasome levels by exposing cell lines to IFN-γ (100 U/ml)
for 6-72 h. Indeed, IFN-γ transiently increased (peaks be-
tween 24-48 hours) mRNA levels of β5i, β1i, and β2i up to
8-fold, 30-fold and 4-fold, respectively. In contrast, consti-
tutive subunits slightly decreased after 24 h (Figure 2A).
For comparison, parental cells essentially showed a similar
pattern of immunoproteasome mRNA induction, except
that the degree of induction was markedly lower than
in bortezomib-resistant cells; only THP1/WT cells dis-
played a higher induction compared to THP1/BTZ200
(Figure 2B). These findings were corroborated at the pro-
tein level using Western blot analysis (Figure 2C-D) and
the ELISA-based ProCISE assay (Additional file 2), illus-
trating an increase in β5i β1i, and β2i subunit expression
along with a decreased expression of constitutive sub-
units after IFN-γ exposure. To determine whether or not
the mutated and/or wild type allele of PSMB5 was down-
regulated, mutation-specific primers (for Ala49Thr), wild
type-specific primers, and primers for total exon 2 of
PSMB5 were developed to quantify the contribution of
the mutated allele in 8226/BTZ100 and THP1/BTZ200
before and after 48 hours of IFN-γ exposure. First, ampli-
fication curves showed that 8226/BTZ100 cells harboredbortezomib-sensitive 8226 (MM), THP1 (AML) and CEM (ALL)
, and β2) and immunoproteasome subunits (β5i, β1i, and β2i) were
CEM/WT, THP1/WT, 8226/BTZ100, THP1/BTZ200 and CEM/BTZ200 cells.
e mean (± SD) of 3 separate experiments.
β1i
β1















Figure 2 Effect of IFN-γ exposure on constitutive and immunoproteasome subunits mRNA and protein levels in bortezomib-resistant
and bortezomib-sensitive 8226 (MM), THP1 (AML) and CEM (ALL) cells. (A) Expression levels of β5, β1, β2, β5i, β1i and β2i mRNA were
monitored after 6-72 hrs exposure of 8226/BTZ, THP1/BTZ, CEM/BTZ and (B) their parental counter parts to 100 U/ml IFN-γ. Results are presented
relative to untreated controls conditions and depicted as mean (± SD) of 3 individual experiments for bortezomib-resistant cells and mean of two
experiments performed in duplicate for parental cells. (C) Western blot analysis of β1i, β1, β5i and β5 protein expression after 6-72 hrs exposure
of 8226/BTZ, THP1/BTZ, CEM/BTZ and (D) their parental counter parts to 100 U/ml IFN-γ. One representative example of 3 experiments is shown.
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mRNA compared to parental 8226/WT cells. However,
the expression of total exon 2 of PSMB5 was about 3-
fold higher in 8226/BTZ100 cells compared to 8226/WT
cells, which implies that mutated Ala49Thr in the resist-
ant cells outweighs unmutated PSMB5 (Additional file 3).
Similar results were observed for THP1 cells, although
THP1/BTZ200 cells expressed slightly higher levels of
unmutated PSMB5 compared to THP1/WT (Additional
file 3). Furthermore, expression of these PSMB5 variants
was determined in the resistant cell lines exposed to IFN-γ.
Of note, total PSMB5 expression was decreased in cells
exposed to IFN-γ compared to unexposed cells (8226/
BTZ100; 24% decrease, and for THP1/BTZ200; 42%
decrease). Moreover, unmutated as well as mutated
PSMB5 expression decreased after exposure to IFN-γ.
Specifically, unmutated PSMB5 expression decreased
23% in 8226/BTZ100 cells and 48% in THP1/BTZ200
cells. Mutated PSMB5 expression decreased 14% in 8226/
BTZ100 and 30% in THP1/BTZ200 cells. Accordingly,
both mutated and unmutated PSMB5 expression declined
after IFN-γ exposure, with dominance for unmutated
PSMB5 (Additional file 3).
Collectively, bortezomib-resistant hematologic tumor
cells possess the capacity to markedly induce immu-
noproteasome levels upon IFN-γ stimulation, thereby
outweighing mutated and unmutated constitutive prote-
asome levels.
IFN-γ stimulation confers increased proteasome catalytic
activity and HLA Class-I molecule expression
To determine whether increased immunoproteasome
expression also impacts proteasome catalytic activity, an
intact cell-based assay was used to measure the three
catalytic proteasome activities in the three bortezomib-
resistant cell lines before and after 6-72 h incubation
with IFN-γ. Following IFN-γ exposure, chymotrypsin-
like proteasome activity increased up to 2.5-fold com-
pared to unstimulated controls, and trypsin-like activity
increased up to 1.5-fold, whereas caspase-like activity
was slightly decreased (Figure 3A). WT cell lines ex-
posed to IFN-γ displayed only modest increments in
chymotrypsin-like and trypsin-like proteasomal acti-
vities, whereas caspase-like activity decreased by 50-
65% in 8226 and THP1 cells, but not in CEM/WT cells
(Figure 3B). Subdividing the chymotrypsin-like activity
into β5 and β5i catalytic activities with subunit-specific
probes showed that β5 activity did not change in cell
extracts of 8226/BTZ100 and CEM/BTZ200 cells upon
stimulation with IFN-γ, whereas in THP1/BTZ200 cells
the β5 activity declined after 48 h of IFN-γ exposure.
For all three parental and bortezomib-resistant cell
lines, β5i and β1i activities increased upon stimula-
tion with IFN-γ (Figure 3C). Consistent with increasedproteasome catalytic activity, increased expression of
cell surface HLA Class I was also observed, particu-
larly in 8226/BTZ100 cells (2-fold) and CEM/BTZ200 and
THP1/BTZ200 cells (1.5-fold increase). HLA Class I ex-
pression in WT cells was increased moderately (up to 50%)
(Additional file 4).
IFN-γ promotes sensitization of bortezomib-resistant cell
lines to cell death by proteasome inhibitors
As we have recently shown that mutated constitutive β5
subunit is a critical factor in conferring resistance to
bortezomib [8,9], we hypothesized that IFN-γ-induced
upregulation of non-mutated immunoproteasome in
bortezomib-resistant cells may re-introduce the targeting
capacity of bortezomib and other selective immunopro-
teasome inhibitors, thereby restoring drug sensitivity.
Indeed, cell growth inhibition assays demonstrated that
pre-exposure to IFN-γ sensitized 8226/BTZ100 cells
4-fold for bortezomib (Figure 4A), 2-fold for Carfilzomib
(CFZ; Figure 4B) and 7-fold for the immunoproteasome
inhibitor ONX 0914 (Figure 4C). Similar profiles were
observed for THP1/BTZ200 after IFN-γ exposure, though
with slightly lower sensitization factors than for 8226/
BTZ100 cells (Figure 4A-C). Sensitization factors for bor-
tezomib and carfilzomib were the lowest for CEM/
BTZ200 cells, but still 3-fold sensitization for ONX
0914 (Figure 4A-C). IC50 values were found to differ
significantly between experiments without and with
IFN-γ for all high bortezomib-resistant cell lines and
drugs. Sensitization impact induced by IFN-γ was further
explored in 8226 cells with low levels of bortezomib resis-
tance (8226/BTZ7). Herein, IFN-γ significantly restored
parental cell sensitivity to ONX 0914 (p = 0.03) (Figure 4D).
For comparison, parental 8226, THP1 and CEM cells
were not sensitized or only marginally sensitized to
bortezomib, carfilzomib or ONX 0914 after IFN-γ expos-
ure (Additional file 5). Consistently, when PBMCs from
healthy individuals were exposed for 24 hours to a con-
centration range of IFN-γ, they also upregulated immu-
noproteasome subunits, but did not became sensitized
for bortezomib (Additional file 6). A composite summary
of the impact of IFN-γ-induced upregulation of immuno-
proteasomes on the sensitivity of bortezomib-resistant
cells to bortezomib, carfilzomib and ONX 0914 is depicted
in Additional file 7.
Restoration of drug sensitivity to (immuno)proteasome
inhibitor after IFN-γ exposure was further confirmed by
apoptosis induction and activation of PARP cleavage.
Western blot analysis revealed a marked increase in
cleaved PARP and NOXA expression in bortezomib-
resistant cells when bortezomib exposure was preceded
by IFN-γ as compared to bortezomib alone (Figure 5).
Next, we examined the accumulation of polyubiquiti-
nated proteins as a hallmark of proteasome inhibition in
Figure 3 (See legend on next page.)
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Figure 3 Impact of IFN-γ exposure on proteasome catalytic activity in intact cells and cell extracts of bortezomib-resistant and
bortezomib-sensitive 8226 (MM), THP1 (AML) and CEM (ALL) cells. (A) Chymotrypsin-like, caspase-like and trypsin-like proteasome activity in
intact bortezomib-resistant and (B) bortezomib-sensitive 8226, THP1 and CEM cells before and after 6-72 hrs exposure 100 U/ml IFN-γ. Results are
presented relative to untreated controls and represent the mean (± SD) of 3 individual experiments. (C) β5, β5i and β1i-associated catalytic activity in
cell extracts of 8226/WT, 8226/BTZ100, THP1/WT, THP1/BTZ, CEM/WT, and CEM/BTZ200 cells after 24 hr and 48 hr exposure to 100 U/ml IFN-γ. Activity
assays in cell extracts employed subunit-specific substrates. Results represent the mean (± SD) of 3 experiments.
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http://www.jhoonline.org/content/7/1/7bortezomib-resistant cells upon pre-exposure to IFN-γ
followed by incubation with the bortezomib concentra-
tion they were stably growing in. Exposure to bortezo-
mib or IFN-γ alone showed a minimal accumulation of
polyubiquitinated proteins in bortezomib-resistant cells.
In contrast, pre-exposure to IFN-γ in combination withFigure 4 Sensitivity of bortezomib-resistant cell lines to proteasome
THP1/BTZ200 and CEM BTZ/200 cells to (A) bortezomib (BTZ) (with and wi
(C) ONX 0914 (with and without IFN-γ), compared to parental cell sensitiv
ONX 0914, as determined by MTT cytotoxicity assays after 4 days drug expo
CFZ and ONX 0914 addition. Results represent the mean (± SD) of 3 individ
cells exposed or unexposed to IFN-γ.bortezomib introduced a major accumulation of polyubi-
quitinated proteins pointing to restoration of proteasome
inhibitory activity of bortezomib and subsequent induction
of apoptosis (Figure 5). Similar results were noted with
cells pre-exposed to IFN-γ and subsequently to ONX 0914
for 24 hours (Additional file 8).inhibitors after IFN-y pre-exposure. Sensitivity of 8226/BTZ100,
thout IFN-γ), (B) Carfilzomib (CFZ) (with and without IFN-γ), and
ity, and (D) and the sensitivity of 8226/BTZ7 cells to BTZ, CFZ, and
sure. Pre-exposure with 100 U/ml IFN-y was for 24h prior to 4-day BTZ,
ual experiments. P-values indicate differences between BTZ-resistant
PARP full
PARP cleaved 
Bortezomib       - +         - +             - +         - + - +          - + 
8226/BTZ100 CEM/BTZ200THP1/BTZ200
















Figure 5 Apoptosis induction and accumulation of ubiquitinated proteins in bortezomib-resistant 8226 (MM), THP1 (AML) and CEM
(ALL) cells after sensitizing cells for bortezomib with IFN-γ. Western blot analysis of PARP cleavage and expression of NOXA as indicators of
apoptosis and accumulation of polyubiquitinated proteins in untreated cells, after 24 h exposure to bortezomib (100 nM for 8226/BTZ100 and 200 nM
for both CEM/BTZ200 and THP1/BTZ200), single IFN-γ (100 U/ml), or the combination of IFN-γ and bortezomib.
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sensitization of bortezomib-resistant cell lines
To provide evidence that upregulation of β5i and/or β1i
by IFN-γ was responsible for the observed sensitization
to proteasome inhibitor, siRNA-dependent downregula-
tion of PSMB8 (β5i) and PSMB9 (β1i) was applied in
THP1/BTZ200 cells prior to exposure to IFN-γ. Under
these conditions, mRNA levels of PSMB8 and PSMB9
remained significantly (P = 0.03) suppressed for approxi-
mately 80%, even after exposure to IFN-γ, compared to
non-target siRNA (Figure 6A-B). Expression of β5i and
β1i protein was suppressed for 58% and 78% after 48 h of
PSMB8 and PSMB9 silencing respectively, compared
to non-target control siRNA (Figure 6C). Consistently,
after siRNA downregulation of PSMB8, but not PSMB9,
chymotrypsin-like proteasome catalytic activity signifi-
cantly (P = 0.03) declined to 50% of its control and
remained suppressed after exposure to IFN-γ (Figure 6D).
Lastly, we determined sensitivity to ONX 0914 and borte-
zomib with 4-day MTT cytotoxicity assays after PSMB8
and PSMB9 silencing with or without IFN-γ pre-exposure.
After the sole silencing of PSMB8, THP1/BTZ200 cells be-
came slightly more resistant to bortezomib and ONX
0914, while PSMB9 silencing did not exert any effect
(Figure 7A-B). When cells were exposed to IFN-γ after
PSMB8 silencing, bortezomib and ONX 0914 sensitization
was attenuated. In contrast, exposure to IFN-γ after silen-
cing of PSMB9 expression had less effect on bortezomib
and ONX 0914 sensitization (Figure 7C-D), indicating that
β5i represents the major determinant in exerting apoptosisand growth inhibitory effects of bortezomib and ONX
0914 after exposure to IFN-γ.
Discussion
The present study is the first to document the impact of
IFN-γ on constitutive- and immunoproteasome homeo-
stasis in three bortezomib-resistant tumor cell lines of
different hematologic origin and to assess the implica-
tions for anti-proliferative activity of proteasome inhibi-
tors. Characteristically, the bortezomib-resistant cell lines
largely expressed the mutated form of PSMB5, and
clearly, IFN-γ increased the expression of catalytically ac-
tive immunoproteasome levels in bortezomib-resistant
cells with concurrent downregulation of both mutated
and unmutated alleles of constitutive β5. This property
facilitated sensitization to bortezomib, and an even more
pronounced sensitization to the immunoproteasome in-
hibitor ONX 0914. Sensitization effects were most prom-
inent in 8226/BTZ cells and lowest in CEM/BTZ cells,
which may be related to the fact that CCRF-CEM
leukemia cells have low levels of IFN-γ receptors [30]. At
equal doses of IFN-γ, induction of immunoproteasome
β5i and β1i subunit mRNA and protein expression was
significantly higher (up to 4-fold) in bortezomib-resistant
tumor cells compared to parental cells. Concomitantly,
constitutive proteasome subunits were clearly downregu-
lated at a protein level, but not as much on mRNA levels.
This phenomenon was also reported by others (reviewed
by Ebstein et al [31]), indicating that downregulation

































































































































































































































































































Figure 6 Effect of IFN-γ after siRNA knockdown of immunosubunits PSMB8 (β5i) and PSMB9 (β1i). (A) PSMB8 mRNA expression after
PSMB8 siRNA with and without 100 U/ml IFN-γ for 24h compared to non-target siRNA with and without 100 U/ml IFN-y, (B) PSMB9 mRNA
expression after PSMB9 siRNA with and without 100 U/ml IFN-γ for 24 h compared to non-target siRNA with and without 100 U/ml IFN-γ. Results
are presented as percentage relative to controls (mean (± SD) of 3 individual experiments). (C) β5i protein expression after PSMB8 silencing for
48 h compared to non-target control siRNA (58% downregulation) and protein expression of the mature protein form of β1i after PSMB9 silencing
for 48 h compared to non-target control siRNA (78% downregulation). (D) Chymotrypsin-like activity of non-target siRNA as compared to PSMB8
or PSMB9 siRNA with and without 100 U/ml IFN-y for 24 h. Results are the means of 4 separate experiments. *P < 0.05
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lightcycler RT-PCR technique, a moderate downregula-
tion on mRNA level was detectable. Additionally, in
PBMCs from healthy individuals, the same results were
noticed as in the parental cell lines when exposed to
IFN-γ, and call for further analyses in bortezomib-
resistant patient specimen. It is not clear whether the
upregulation of immunoproteasome levels reflects acompensatory and homeostatic effect after initial downreg-
ulation during bortezomib resistance development. Im-
portantly, increased β5i expression can drive incorporation
of immunoproteasome subunits into prototypic immuno-
proteasomes [32] or facilitate assembly in hybrid types
of proteasomes (β1 + β2 + β5i and β1i + β2 + β5i) [33].
Conceivably, these hybrid forms could compensate for
impaired catalytic activity of constitutive proteasomes
Figure 7 PSMB8 (β5i) siRNA attenuates sensitizing effect of IFN-γ to bortezomib and ONX 0914. Cell growth inhibitory effects of (A) bortezomib
and (B) ONX 0914 after PSMB8 or PSMB9 silencing in THP1/BTZ200 cells. Effects of PSMB8 and PSMB9 silencing on IFN-y sensitization of growth inhibition
of THP1/BTZ200 cells to (C) bortezomib and (D) ONX 0914. Results depicted are the means (± SD) of 3 independent experiments.
Niewerth et al. Journal of Hematology & Oncology 2014, 7:7 Page 12 of 15
http://www.jhoonline.org/content/7/1/7assembled with a mutated β5-subunit. Following use of
β5-selective substrates, chymotrypsin-like catalytic activity
in cell extracts of bortezomib-resistant cells increased 2-4
fold over those of parental cells (Figure 3B). These obser-
vations are consistent with our previous report in which
we observed, using native gel electrophoresis, proficient
catalytic capacity of mutated β5 subunit-harboring protea-
somes in CEM/BTZ cells for chymotrypsin-like probes,
but a diminished inhibitory capacity by bortezomib [9].
Likewise, Kale et al [34] showed that strains of the marine
actinobacterium Salinispora tropica could maintain self-
resistance to the proteasome inhibitor salinosporamide A
by expressing a proteasome variant harboring β5 subunit
mutations similar to those detected in human THP1/BTZ
cells [8,9]. This mutated β5 subunit had retained its ca-
pacity to hydrolyze β5-specific substrates, but displayed a
diminished sensitivity to inhibition by salinosporamide A.
The expanding knowledge of factors determining bor-
tezomib sensitivity or resistance that emerged from cell
line studies (reviewed in ref [35]), still awaits translation
and implementation in a clinical setting. With respect to
the role of immunoproteasomes, a recent report from
our laboratory showed that higher ratios of immunopro-
teasome over constitutive proteasome in acute leukemia
patient samples served as an important parameter for
their ex vivo sensitivity to bortezomib and ONX 0914[19]. In addition, Shuqing et al [36] showed an increase
in constitutive PSMB5 mRNA expression in a myeloma
patient after bortezomib treatment compared to the pre-
treatment sample. Also recently, Leung-Hagensteijn et al
[37] showed that immunoproteasome subunit expression
was decreased in patients with myeloma tumors resist-
ant to bortezomib, compared to bortezomib-sensitive
patients. This study also revealed that the loss of Xbp1
signaling (which is required for plasma cell differentiation
and regulation of unfolded protein response) induced
bortezomib-resistance in MM cell lines and patient cells.
Based on these considerations, strategies that may increase
immunoproteasome levels may merit further exploration
for therapeutic intervention.
Despite the fact that IFN-γ-induced upregulation of
immunoproteasomes facilitates sensitization of bortezomib-
resistant cells to bortezomib and ONX 0914, IFN-γ expo-
sure does not establish full restoration of parental sensitivity
to bortezomib. This may be due to two reasons; first, inhi-
bition of the catalytic activity of the immunoproteasome
alone appears insufficient to exert a cell growth inhibitory
effect. Rather, this requires inhibition of chymotrypsin-
like activity and co-inhibition of caspase-like or trypsin-like
activities [38,39]. Second, the constitutive β5 subunit is
structurally altered in all 3 bortezomib-resistant tumor cell
lines due to mutations in the PSMB5 gene introducing
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bortezomib-binding pocket leading to diminished borte-
zomib binding efficiency [8,9]. This structural alteration
precludes optimal inhibition of the β5 subunit by bortezo-
mib as present in parental cells, thus retaining a significant
degree of bortezomib resistance. These considerations
specifically apply for cells with a high level (> 100-fold)
of bortezomib resistance. In cells (e.g. 8226/BTZ7 cells)
with a more clinically relevant low level (~ 5-fold) re-
sistance to bortezomib, IFN-γ exposure reversed 50% of
bortezomib resistance and achieved parental sensitivity
to ONX 0914 (Figure 4D, Additional file 7). The latter
observation is consistent with data from Huber et al
[40] who showed that incorporation of immunoprotea-
some subunits confers structural alterations in the 20S
proteasome complex, resulting in improved accessibility
of ONX 0914 to the active sites, which would underlie
a mechanism for the largest differential sensitizing effect
observed with ONX 0914 as compared to bortezomib
and carfilzomib.
Knockdown experiments revealed that β5i expression
is critically involved in mediating the proteasome
inhibitor-sensitizing effects in bortezomib-resistant tumor
cells. The role of β5i may first be related to proteasome
assembly, in which β5i is required for processing the β1i
and β2i subunits [41]. Consistently, β5i deficiency delays
immunoproteasome assembly [41]. Beyond increased
immunoproteasome subunit expression after IFN-γ expo-
sure, chymotrypsin-like and trypsin-like proteasome cata-
lytic activities were increased, whereas caspase-like activity
was decreased. Employing subunit activity-specific probes
indicated that the increase in chymotrypsin-like activity
was solely accountable for by the increase in β5i but not
β5 catalytic activity. At the same time, the decrease in
caspase-like activity was solely due to reduced β1 activity
since β1i activity actually increased upon stimulation with
IFN-γ. Thus, our findings in bortezomib-resistant cells
underscore studies showing that replacement of β1 with
β1i decreased caspase-like activity and enhanced β5i-
associated chymotrypsin-like activity [11,12,42]. Immuno-
logically, a rise in chymotrypsin-like activity would result
in the generation of more peptides with hydrophobic
C-terminal residues for presentation on MHC class-I
molecules [11]. As such, a prominent IFN-γ-induced
switch from constitutive to immunoproteasomes in
bortezomib-resistant cells could lead to gain of efficiency
in antigen presentation by increased peptide loading after
immunoproteasome peptide processing. In our study,
PSMB8/β5i-downregulation resulted in a 50% decrease
of chymotrypsin-like activity, whereas β1i downregula-
tion had no effect on any of the three catalytic activities
(data not shown). This phenotype seems fully com-
patible with that of β5i-deficient mice displaying a
50% decrease in the expression of MHC class-I molecules;these alterations were not observed in β1i- or β2i-deficient
mice [13,43,44].
Krüger and Kloetzel [45] suggested that IFN-γ induc-
tion combines enhanced translational activity with a
rapid increase in the pool of polyubiquitinated proteins
that require processing by the proteasome. In this con-
text, the IFN-γ-induced synthesis of immunoprotea-
somes may represent a physiological adaptation to this
cytokine-induced oxidative stress. If cells under these
conditions were to be exposed to proteasome inhibitors,
blocking of functional activity of newly formed immuno-
proteasomes would result in additional accumulation of
polyubiquitinated proteins, causing cell stress and induc-
tion of apoptotic cell death. The bortezomib-resistant
cell lines did reveal accumulation of polyubiquitinated
proteins as in bortezomib-sensitive parental cells but at
higher bortezomib concentrations to which they are
adjusted [8,9]. This is likely due to an adaptive mechanism
in bortezomib-resistant cells to enhance the β5-associated
catalytic capacity to process physiological substrates
(Figure 3B). Interference with this process by IFN-γ in-
duced upregulation of immunoproteasomes and blocking
their function with specific inhibitors could then trigger
accumulation of polyubiquitinated proteins and apoptotic
cell death, hence being in line with the mechanism
proposed by Kruger and Kloetzel [45].Conclusion
Downregulation of β5i subunit expression was identified
as being an important determinant of acquisition of borte-
zomib resistance in cell lines of hematologic malignancies.
The pharmacological implication of this novel finding is
exemplified by the fact that induction of β5i proteasomal
assembly after IFN-γ exposure facilitated restoration of
sensitivity of bortezomib-resistant cells towards bortezo-
mib and in particular to immunoproteasome inhibitors.Additional files
Additional file 1: Table S1. Proteasome subunit primer design and
siRNA sequences.
Additional file 2: Figure S1. Effect of IFN-γ exposure on constitutive
and immunoproteasome subunit protein levels in bortezomib-resistant
and bortezomib-sensitive 8226 (MM), THP1 (AML) and CEM (ALL) cells.
Expression levels of β5, β1, β2, β5i, β1i and β2i protein were analyzed by
ProCISE assay after 6-72 hrs exposure of 8226/BTZ100, THP1/BTZ200,
CEM/BTZ200 cells and their parental counter parts to 100 U/ml IFN-γ.
Protein levels are expressed in ng subunit/μg total protein and data represent
the mean (± SD) of 3 individual experiments.
Additional file 3: Figure S2. Quantification of mutated and unmutated
PSMB5 expression in bortezomib-resistant 8226 (MM) and THP1 (AML)
cells after IFN-γ exposure. mRNA expression of total PSMB5 and unmutated
PSMB5 in; (A) 8226/BTZ100 cells compared to parental 8226 cells, (B) THP1/
BTZ200 compared to parental THP1 cells. Expression of total PSMB5,
unmutated PSMB5, and PSMB5 harboring Ala49Thr mutation in (C); 8226/
BTZ100 cells exposed to 100 U/ml IFN-γ for 48 hours, and (D); THP1/BTZ200
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http://www.jhoonline.org/content/7/1/7cells exposed to 100 U/ml IFN-γ for 48 hours, as determined by lightcycler
RT-PCR analysis.
Additional file 4: Figure S3. Impact of IFN-γ exposure on HLA-Class I
expression in bortezomib-resistant and bortezomib-sensitive 8226 (MM),
THP1 (AML) and CEM (ALL) cells. HLA-ABC expression after 6-72h IFN-γ
exposure in bortezomib-resistant cell lines 8226/BTZ100, CEM/BTZ200,
and THP1/BTZ200 and their parental bortezomib-sensitive counterparts.
Results represent mean fluorescence index relative to unexposed control
cells. Results depict the mean (± SD) of 3 individual experiments.
Additional file 5: Figure S4. Sensitivity of parental bortezomib-sensitive
cell lines to proteasome inhibitors after IFN-γ pre-exposure. Sensitivity of
8226/WT, THP1/WT and CEM/WT cells to (A) bortezomib (BTZ) (with and
without IFN-γ), (B) Carfilzomib (CFZ) (with and without IFN-γ), and (C) ONX
0914 (with and without IFN-γ) as determined by MTT cytotoxicity assays
after 4 days drug exposure. Pre-exposure with 100 U/ml IFN-y was for 24 h
prior to 4-day bortezomib, carfilzomib and ONX 0914 addition. Results
represent the mean (± SD) of 3 individual experiments.
Additional file 6: Figure S5. Sensitivity of PBMCs of healthy
individuals to bortezomib after IFN-γ pre-exposure and upregulation
of immunoproteasome subunits. (A) Sensitivity of PBMCs to bortezomib
(with and without 100 U/ml IFN-γ), as determined by MTT cytotoxicity
assays after 48 hours of drug exposure. (B) mRNA expression of
immunoproteasome subunits PSMB8 and PSMB9 upon exposure to various
concentrations of IFN-γ for 24 hours. Results represent the mean (± SD) of 3
healthy individuals.
Additional file 7: Table S2. Summary effect of IFN-γ exposure on
growth inhibition of bortezomib-resistant and bortezomib-sensitive 8226,
THP1 and CEM cells by bortezomib, carfilzomib and ONX 0914.
Additional file 8: Figure S6. Accumulation of ubiquitinated proteins in
bortezomib-resistant 8226 (MM), THP1 (AML) and CEM (ALL) cells after
sensitizing cells for ONX 0914 with IFN-γ. Western blot analysis of accumulation
of polyubiquitinated proteins in untreated cells, after 24 h exposure to
ONX 0914 (250 nM for 8226/BTZ100, 566 nM for CEM/BTZ200 and 1376 nM
for THP1/BTZ200), single IFN-γ (100 U/ml), or the combination of IFN-γ
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